MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Josep Tabernero Head, Medical Oncology Department, MD PhD
Vall d' Hebron Institute of Oncology (VHIO) P. Vall d'Hebron 119-129 08035 Barcelona, Spain
Study ChairKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chu Sart Tilman
Liège, Belgium
- Centro Riferimento Oncologico
Aviano, Italy
- Irccs Ospedale San Raffaele
Milan, Italy
- Vall D'Hebron Barcelona Hospital
Barcelona, Spain
- Centro Integral Oncologico Clara Campal
Madrid, Spain
- Start Madrid. Fundacion Jimenez Diaz
Madrid, Spain
- Nccc Clinical Trials Pharmacy, Northern Centre for Cancer Care
Newcastle upon Tyne, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Aug 2017
- Primary completion
- 22 Oct 2019
- Completion
- 8 Jan 2020
- Last update posted
- 28 Sept 2021
- Registered enrollment
- 28
- Registry id
- NCT03403725
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.